Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812);JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

Leukemia

Volumn 21, Issue 11, 2007, Pages 2386-2390

  Vicente, C ^a,b   Vazquez I ^a   Marcotegui, N ^a   Conchillo, A ^a   Carranza, C ^a   Rivell, G ^a   Bandres E ^a   Cristobal, I ^a   Lahortiga, I ^a   Calasanz, M J ^b   Odero, M D ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; JANUS KINASE 2; MOLECULAR MARKER; PHENYLALANINE; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; INCIDENCE; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; WORLD HEALTH ORGANIZATION;

EID: 35648996038     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405004     Document Type: Erratum

References (19)

1. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004, 80-97.
2. Ihle JN, Gilliland DG. Jak2: Normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17: 8-14.
3. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
4. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
5. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
6. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
7. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25: 1434-1436.
8. Frohling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Dohner H et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006; 107: 1242-1243.
9. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971-978.
10. Suzuki M, Abe A, Kiyoi H, Murata M, Ito Y, Shimada K et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. Leukemia 2006; 20: 1168-1169.
11. Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML. Leukemia 2007; 21: 183-184.
12. Dohner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Dohner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica 2006; 91: 1569-1570.
13. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
14. Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 2006; 38 1071-1076.
15. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098-2100.
16. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 2006; 108: 3548-3555.
17. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108b: 1377-1380.
18. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005; 65: 9152-9154.
19. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004; 20: 1233-1240.